Clinical trials: Atopic Skin
Dermatitis, Atopic
Effect of Different Skin Creams on TEWL
Prospective, single center, clinical pilot study to test the hypothesis that lipid rich EpiCeram® is superior in improving skin barrier function compared to Aveeno Daily Moisturising Sheer Hydration Lotion®.
- Trial name
- NCT03663673
- Testing
- EpiCeram, Aveeno Daily Moisturising Sheer Hydration Lotion®
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Atopic Dermatitis, Skin Diseases
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different…
- Conditions
- Atopic Dermatitis, Skin Diseases, Eczema
- Trial name
- BRONTE (NCT04818138)
- Testing
- Narrowband UVB phototherapy, Broadband UVB phototherapy
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- Women's College Hospital
Asthma, Allergic Rhinitis
Fractional Exhaled Nitric Oxide (FeNO) Result Prediction Factors in Children With Allergic Diseases
In about 800 children with allergic diseases (asthma, allergic rhinitis, atopic dermatitis) the investigators will retrospectively and cross-sectionally analyze the influence/correlation of diagnosis, treatment methods, allergy…
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- NCT00815984
- Testing
- measurements of lung function tests
- Where
- Poland
- Volunteers
- 800 people
- Sponsor
- Medical University of Lodz
Dermatitis Atopic
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with…
- Trial name
- NCT06790121
- Testing
- Lunsekimig
- Where
- 52 sites in United States, Czechia and 2 more
- Volunteers
- 150 people
- Sponsor
- Sanofi
Atopic Dermatitis
Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments
Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting both children (15- 20%) and adults (2-5%). The pathogenesis of AD is complex and multifactorial, including skin barrier dysfunction and immune…
- Trial name
- NCT07577921
- Testing
- Investigational cosmetic product RV4427C
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatologic Disease
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in…
- Trial name
- NCT05607901
- Testing
- Tacrolimus ointment, Hydrocortisone 1% cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Dermatitis, Atopic
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4…
- Trial name
- NCT02001181
- Testing
- Tofacitinib ointment 20mg/g
- Where
- 5 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
Atopic Dermatitis (Eczema)
The Effects of an Oral Prebiotic and an Oral Synbiotic Supplement in Combination With a Topical Lotion and Soap On Eczema
The purpose of this study is to examine the effects of 2 dietary supplements (an oral prebiotic and an oral synbiotic) in combination with a topical lotion, and an unscented soap on eczema severity, various skin measures (such as…
- Trial name
- NCT07041892
- Testing
- Prebiotic Supplement + Synbiotic Supplement + Topical Lotion + Unscented Soap
- Where
- Poland
- Volunteers
- 34 people
- Sponsor
- Codex Labs Corporation
Alopecia Areata
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation.
- Trial name
- SIGNAL-AA (NCT06018428)
- Testing
- bempikibart (ADX-914)
- Where
- 33 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Q32 Bio Inc.
Dermatitis, Atopic
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07767253
- Testing
- 611
- Where
- 5 sites in China
- Volunteers
- 246 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Effects of Abrocitinib Treatment on Skin Barrier Function
Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.
- Trial name
- AbroSkib (NCT05140239)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Prof. Dr. Stephan Weidinger
Atopic Dermatitis
Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis
Prospective single-blinded placebo-controlled cross-over study, among adult patients suffering from moderate-to-severe atopic dermatitis (AD), insufficiently responsive to topical and systemic treatment.
- Trial name
- NCT04613037
- Testing
- Fecal Microbial Transplantation
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis
The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in…
- Trial name
- NCT05984420
- Testing
- LimpiAD 2,5% plus cream, Vehicle, Emollient
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Aileens Pharma SRL
Atopic Dermatitis
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
- Trial name
- NCT05509023
- Testing
- ADX-914
- Where
- 24 sites in United States
- Volunteers
- 102 people
- Sponsor
- Q32 Bio Inc.
Atopic Dermatitis, Atopic Eczema
Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.
- Trial name
- AMB-WEI-1052-I (NCT01179529)
- Testing
- Omalizumab (Xolair®)
- Where
- Germany
- Sponsor
- Technical University of Munich
Atopic Dermatitis
Clinical Relevance of Scratching and Sleep in Atopic Dermatitis
Atopic Dermatitis (AD), otherwise known as (atopic) eczema, is a chronic relapsing inflammatory skin disease. For difficult-to-treat AD, treatment options are limited.
- Trial name
- NCT05467046
- Testing
- Smartwatch system
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Dermatitis, Atopic
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- SOLO 2 (NCT02277769)
- Testing
- Dupilumab
- Where
- 93 sites in United States, Canada and 9 more
- Volunteers
- 708 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma, COPD
An Evaluation of 9MW1911 Injection in Healthy Subjects
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05803902
- Testing
- Experimental drug 9MW1911
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.